Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a single arm open-label multicenter phase I/II investigation of combination lenalidomide/Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma. This is the first study to examine a naked anti-CD19 monoclonal antibody in relapsed CNS lymphoma patients as well as the combination of anti-CD19 antibody plus an Immunomodulatory imide drugs (IMiDs) in CNS lymphomas. This study will also test the novel hypothesis that Tafasitamab enhances blood-brain barrier permeability, a potential property that could have broad clinical implications.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nawrotowy chłoniak mózgu lub opon mózgowych typu DLBCL (duże komórki B)
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na uczestnictwo (możliwość samoopieki)
- •Wystarczające liczby białych krwinek, płytek krwi i prawidłowa funkcja nerek
- •Prawidłowa funkcja wątroby (choć mogą być lekkie odchylenia)
- •Przewidywane przeżycie co najmniej 2 miesiące
- •Zdolność do podpisania świadomej zgody na udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of California, San Francisco
San Francisco, United States
Trial contact
UCSF Hematopoietic Malignancies Clinical Trial Recruitment
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.